臨床走到哪裡,與公開了什麼結果
這份比較涵蓋中國、日本、韓國的 18 項資產。每項用同一組問題檢查:原研是誰?標的是什麼、用哪一類降解方式?最高試驗階段與目前狀態為何?公開的結果屬於哪些患者、用了什麼對照?具名資產授權是否公開?試驗階段與人體證據各有一欄。完成給藥代表已有人體暴露;要判斷療效,還要知道量到什麼、在哪一群人身上量到。 [P00]

典型雙功能降解劑可把 E3 泛素連接酶與靶蛋白拉近,促使靶蛋白被加上泛素標記,之後由蛋白酶體分解。分子膠可用另一種方式穩定連接酶與靶蛋白的結合,抗體偶聯形式還多了一個遞送步驟。能否在合適組織、對特定病人產生效果,仍須回到人體試驗。美國食藥署在 5 月核准 vepdegestrant 用於曾接受內分泌治療的特定 ESR1 突變晚期乳癌患者,8 月則加速核准 iberdomide 用於指定多發性骨髓瘤組合療法。每一項決定對應各自的適應症與證據。 [P20] [P21] [P30]

日中進入後期,第三期各自要證明什麼
百濟神州的 tacabrutideg 用於降解 BTK。CaDAnCe-101 在 EHA 公布的 CLL/SLL 第一期開放標籤隊列中,67 人有 57 人出現反應,整體反應率 85.1%,口徑包含伴淋巴球增多的部分反應。11 月公司宣布,復發或難治 CLL 的關鍵第二期部分達主要反應率終點。這些反應率支持繼續開發,對 pirtobrutinib 的第三期則要回答,降解劑能否比已可使用的治療延長無惡化存活。查核的第三期裡,兩項招募、一項進行中但停止招募,登錄均未張貼第三期結果。 [P01] [P22] [P23]
安斯泰來的 setidegrasib 鎖定 KRAS G12D。已發表的第一期研究中,報告所述非小細胞肺癌二、三線隊列為 32 人,客觀反應率 37.5%;所述胰臟癌二、三線隊列為 21 人,客觀反應率 24%。兩個數字分屬不同癌別的單臂隊列。胰臟癌第三期在化療上加 setidegrasib 或安慰劑,以整體存活為主要終點;經治療肺癌的第三期與 docetaxel 比較,主要終點為無惡化存活與整體存活。 [P02] [P24]

真正會改變這兩個後期資產位置的是隨機結果。屆時能支持多少臨床價值,要看主要終點、用藥線別、對照和收案條件。前面兩組數據各自服務自己的病種,把它們排成一張反應率排行榜,只會把疾病與設計的差異一起排進去。
口服前列腺癌與外用雄性禿,各量不同結果
中國的雄性激素受體(AR)管線,說明為什麼給藥途徑要和疾病放在一起。海創 HP518、齊魯 QLH12016 和恆瑞 HRS-5041 在轉移性前列腺癌已交出早期人體觀察,涵蓋開放標籤安全性、藥物動力學及初步活性或前列腺特異抗原(PSA)反應。同一資產可以同時有單藥第一期結果與階段較後的合併試驗。海創的登錄與公司公告分別列招募、單藥試驗擬暫停,兩個資訊都應保留。 [P05] [P06] [P07] [P31] [P32] [P33]
開拓的 GT20029 是雄性禿外用在研藥。中國第二期收了 180 名男性,12 週後比較目標區非毳毛毛髮數變化,以載體作對照,療效結果已經同儕審查發表。開拓公布的另一項中國痤瘡第二期也達到主要終點。PSA、毛髮計數與痤瘡終點各自回答不同病人的問題,也各自需要相稱的對照和耐受性資料。 [P03] [P25] [P34]


韓國案例提醒,授權一定要對到資產
韓國列入的資產都在早期。Ubix 的 UBX-303061 在復發或難治 B 細胞惡性腫瘤招募第一期;Pin Therapeutics 宣布 CK1α 分子膠 PIN-5018 在韓國完成首例給藥。Orum 的 ORM-1153 也已完成第一期首例給藥,為一項以 CD123 導引的 GSPT1 降解劑抗體偶聯藥物。這些公開事件證實開發已進臨床,各資產可比較的療效數據仍未公開。 [P13] [P18] [P19]
2023 年,BMS 曾用 1 億美元首付取得 Orum 另一項資產 ORM-6151;Orum 在 2026 年 9 月公告該資產第一期試驗停止。ORM-1153 是另一個在研藥。Janssen 與 Prazer 在 2026 年簽的是平台研究與授權,未公布個別資產與金額。Cullgen 與安斯泰來先前另簽探索和選擇權合作,授權方申報已收到 3,500 萬美元首付。這筆款對應該平台合作,安斯泰來的 setidegrasib 與本表的 Cullgen 具名資產各自保留自己的授權欄。 [P16] [P17] [P19] [P27] [P28] [P29]

中日韓用同一把尺
E0 代表有登錄或公司公告,查得文件尚未直接確認給藥或公開可解讀結果。E1 為已給藥或完成暴露,可包括早期安全、耐受性或藥物暴露。E2 為公開的單臂療效訊號,或沒有完整對照結果的公司療效摘要。E3 為已公開的對照療效結果,適用於實際的對照組和終點。表內級別依各資產查得的最高人體結果記錄,高階試驗可同時只有早期數據,終止試驗保留歷史階段與目前狀態。
| 原研地 | 原研/資產 | 標的/機制 | 最高收錄階段與狀態 | 人體證據 | 授權 | 來源 |
|---|---|---|---|---|---|---|
| 中國 | BeOne Medicines / BeiGene / Tacabrutideg (BGB-16673) | BTK / CDAC/嵌合降解劑 | 第三期 · 查核的三項第三期中,兩項招募、一項進行中但停止招募 | E2 · 第一期 CLL/SLL 有反應;公司稱復發難治 CLL 關鍵第二期達主要終點;第三期對照結果未公開 | 未公開 | [P01] [P22] [P23] |
| 日本 | Astellas Pharma / Setidegrasib (ASP3082) | KRAS G12D / PROTAC/蛋白降解劑 | 第三期 · 胰臟癌及肺癌第三期招募中 | E2 · 第一期肺癌與胰臟癌反應已發表;第三期結果未公開 | 未公開 | [P02] [P24] |
| 中國 | Kintor Pharmaceutical Limited (Suzhou Kintor) / GT20029 | 雄性激素受體(AR) / PROTAC | 第二期 · 中國雄性禿第二期完成;痤瘡第二期已公布摘要 | E3 · 雄性禿有同儕審查的隨機載體對照療效;痤瘡為另一適應症的公司摘要 | 未公開 | [P03] [P25] [P34] |
| 中國 | Hinova Pharmaceuticals Inc. / HP518 | 雄性激素受體(AR) / PROTAC | 第一/二期 · 登錄仍列中國研究招募;公司報告列單藥試驗擬暫停 | E2 · 轉移性去勢抗性前列腺癌開放標籤第一期已發表 | 未公開 | [P05] [P32] |
| 中國 | Qilu Pharmaceutical / QLH12016 | AR / PROTAC | 第一/二期 · 一項合併試驗招募中;另一項登錄尚未招募 | E2 · ESMO 第一期摘要報告已治療前列腺癌的早期 PSA 反應 | 未公開 | [P06] [P33] |
| 中國 | Hengrui / HRS-5041 | AR / 降解劑 | 第一期 · 單藥及合併劑量探索登錄皆列招募 | E2 · ASCO 第一期摘要報告前列腺癌各劑量組的早期 PSA 反應 | 未公開 | [P07] [P31] |
| 中國 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. / HRS-1358 | 雌激素受體(ER) / PROTAC | 第一/二期 · 乳癌合併試驗登錄招募中 | E0 · 已查文件未公開可解讀的人體結果 | 未公開 | [P08] |
| 中國 | BeOne Medicines / BeiGene / BGB-45035 | IRAK4 / CDAC/嵌合降解劑 | 第二期已終止 · 類風濕關節炎研究終止;先前第一期完成 | E1 · 第一期有人體試驗紀錄;各組療效未公開;登錄載明效益風險不利 | 未公開 | [P09] |
| 中國 | InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. / ICP-490 | IKZF1 (Ikaros); IKZF3 (Aiolos) / CRBN 分子膠 | 第一/二期 · 骨髓瘤登錄狀態未知;淋巴瘤方案尚未招募 | E0 · 已查文件未公開可解讀的臨床結果 | 未公開 | [P10] |
| 中國 | InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. / ICP-538 | VAV1 / CRBN 分子膠 | 第一期 · 健康受試者研究登錄招募中 | E0 · 已查文件未公開人體耐受性或藥效學結果 | 未公開 | [P11] |
| 中國 | Haisco Pharmaceutical Group Co., Ltd. / HSK29116 | BTK / PROTAC | 第一期 · 登錄狀態未知 | E0 · 已查文件未公開可解讀的人體結果 | 未公開 | [P12] |
| 韓國 | Ubix Therapeutics / UBX-303061 | BTK / PROTAC/嵌合降解劑 | 第一期 · B 細胞惡性腫瘤試驗招募中 | E0 · 登錄列劑量和安全性目標;結果未公開 | 未公開 | [P13] |
| 中國 | Haisco Pharmaceutical Group Co., Ltd. / HSK40118 | 突變 EGFR / PROTAC | 第一期 · 登錄最後於 2023 年 9 月列招募,目前狀態未確定 | E0 · 已查文件未公開可解讀的人體結果 | 未公開 | [P14] |
| 中國 | BeOne Medicines / BG-75098 | CDK2 / CDAC | 第一期 · 實體腫瘤試驗招募中 | E0 · 已查文件未公開可解讀的人體結果 | 未公開 | [P15] |
| 中國 | Cullgen (Gyre Therapeutics / GNI Group) / CG001419 | TRK / PROTAC/蛋白降解劑 | 第一期;另列第一/二期方案 · 健康受試者第一期完成;中國第一/二期方案的劑量遞增進行中 | E1 · 有人體暴露紀錄;可解讀的病人療效未公開 | Cullgen 其他平台協議不歸入本資產 | [P16] [P29] |
| 中國 | Cullgen (Gyre Therapeutics / GNI Group) / CG009301 | GSPT1 / 蛋白降解劑 | 第一期 · 中國血液腫瘤劑量遞增招募中 | E0 · 已查文件未公開可解讀的人體結果 | Cullgen 其他平台協議不歸入本資產 | [P17] [P29] |
| 韓國 | Pin Therapeutics / PIN-5018 | CK1α / 分子膠降解劑 | 第一期 · 公司宣布在韓國完成首例給藥 | E1 · 公司證實首例用藥;臨床結果未公開 | 未公開 | [P18] |
| 韓國 | Orum Therapeutics / ORM-1153 | CD123 / GSPT1 / 降解劑抗體偶聯藥物(DAC) | 第一期 · 已給首例;登錄招募中 | E1 · 首例給藥已證實;反應結果未公開 | 具名資產授權未公開;早期 ORM-6151 交易另列 | [P19] [P27] |
下載管線表 CSV。資料是選定樣本。國別依原研或主導開發者,保留試驗地區與後續公司歸屬的差異。未公開的結果或條款依截點記錄;登錄各有更新日期,與公司公告可能存在時間差。具名資產授權與獨立平台合作各自有對應的條目或文字。
會改變這份盤點的,是用合適對照量出的療效。BTK 降解藥需要面對已上市的抑制劑。 [P01]
若有更正,請提供試驗登錄編號或交易名稱、一手文件和公布日期。本文供產業研究,不構成醫療或投資建議。
常見問題
中國哪個 BTK 降解劑有人體結果與第三期頭對頭試驗?
百濟神州的 tacabrutideg 用於降解 BTK。CaDAnCe-101 在 EHA 公布的 CLL/SLL 第一期開放標籤隊列中,67 人有 57 人出現反應,整體反應率 85.1%,口徑包含伴淋巴球增多的部分反應。11 月公司宣布,復發或難治 CLL 的關鍵第二期部分達主要反應率終點。這些反應率支持繼續開發,對 pirtobrutinib 的第三期則要回答,降解劑能否比已可使用的治療延長無惡化存活。查核的第三期裡,兩項招募、一項進行中但停止招募,登錄均未張貼第三期結果。 [P01] [P22] [P23]
安斯泰來的 setidegrasib 有哪些人體證據?
安斯泰來的 setidegrasib 鎖定 KRAS G12D。已發表的第一期研究中,報告所述非小細胞肺癌二、三線隊列為 32 人,客觀反應率 37.5%;所述胰臟癌二、三線隊列為 21 人,客觀反應率 24%。兩個數字分屬不同癌別的單臂隊列。 [P24]
安斯泰來的 setidegrasib 第三期試驗用什麼對照?
胰臟癌第三期在化療上加 setidegrasib 或安慰劑,以整體存活為主要終點;經治療肺癌的第三期與 docetaxel 比較,主要終點為無惡化存活與整體存活。 [P02]
亞洲哪個外用 AR 降解劑有對照毛髮計數結果?
開拓的 GT20029 是雄性禿外用在研藥。中國第二期收了 180 名男性,12 週後比較目標區非毳毛毛髮數變化,以載體作對照,療效結果已經同儕審查發表。開拓公布的另一項中國痤瘡第二期也達到主要終點。PSA、毛髮計數與痤瘡終點各自回答不同病人的問題,也各自需要相稱的對照和耐受性資料。 [P03] [P25] [P34]
韓國哪些降解藥已進入人體試驗,公開到哪一步?
韓國列入的資產都在早期。Ubix 的 UBX-303061 在復發或難治 B 細胞惡性腫瘤招募第一期;Pin Therapeutics 宣布 CK1α 分子膠 PIN-5018 在韓國完成首例給藥。Orum 的 ORM-1153 也已完成第一期首例給藥,為一項以 CD123 導引的 GSPT1 降解劑抗體偶聯藥物。這些公開事件證實開發已進臨床,各資產可比較的療效數據仍未公開。 [P13] [P18] [P19]
References
- P00
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06846671
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07409272
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06692465
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06155084
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07198633
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05942001
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06679036
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07100938
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05719701
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07535099
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT04861779
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06590961
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06050980
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07226349
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06636500
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07347171
- 18 selected assets; China 14, Japan 1, South Korea 3. | issuer (prnewswire.com) | | https://www.prnewswire.com/news-releases/pin-therapeutics-initiates-first-patient-dosing-of-ck1-degrader-pin-5018-in-phase-1-trial-302624301.html
- 18 selected assets; China 14, Japan 1, South Korea 3. | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07809906
- P01
- Tacabrutideg (BGB-16673) · NCT06846671 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06846671
- Tacabrutideg (BGB-16673) · NCT06973187 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06973187
- Tacabrutideg (BGB-16673) · NCT06970743 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06970743
- Tacabrutideg (BGB-16673) · BTK | trial investigators or issuer (beonemedicines.com) | | https://beonemedicines.com/wp-content/uploads/2026/11/BeOne-pipeline-4Nov26-Final-.pdf
- P02
- Setidegrasib (ASP3082) · NCT07409272 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07409272
- Setidegrasib (ASP3082) · NCT07566052 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07566052
- Setidegrasib (ASP3082) · KRAS G12D | trial investigators or issuer (pubmed.ncbi.nlm.nih.gov) | | https://pubmed.ncbi.nlm.nih.gov/41879829/?fc=None&ff=20260411131702&v=2.19.0.post6+133c1fe
- P03
- GT20029 · NCT06692465 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06692465
- GT20029 · NCT05428449 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05428449
- GT20029 · Androgen receptor (AR) | trial investigators or issuer (pubmed.ncbi.nlm.nih.gov) | | https://pubmed.ncbi.nlm.nih.gov/41328006/
- P05
- HP518 · NCT06155084 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06155084
- HP518 · NCT05252364 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05252364
- HP518 · Androgen receptor (AR) | issuer (static.cninfo.com.cn) | | https://static.cninfo.com.cn/finalpage/2026-08-27/1225514360.PDF
- P06
- QLH12016 · NCT07198633 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07198633
- QLH12016 · NCT07104110 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07104110
- QLH12016 · AR | trial investigators or issuer (annalsofoncology.org) | | https://www.annalsofoncology.org/article/S0923-7534%2825%2903985-7/abstract
- P07
- HRS-5041 · NCT05942001 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05942001
- HRS-5041 · NCT07115446 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07115446
- HRS-5041 · AR | trial investigators or issuer (ascopubs.org) | | https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3112
- P08
- HRS-1358 · NCT06679036 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06679036
- HRS-1358 · NCT05628870 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05628870
- HRS-1358 · Estrogen receptor (ER) | issuer (static.cninfo.com.cn) | | https://static.cninfo.com.cn/finalpage/2026-08-20/1225483600.PDF
- P09
- BGB-45035 · NCT07100938 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07100938
- BGB-45035 · NCT06342713 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06342713
- BGB-45035 · IRAK4 | trial investigators or issuer (beonemedicines.com) | | https://beonemedicines.com/wp-content/uploads/2026/11/BeOne-pipeline-4Nov26-Final-.pdf
- P10
- ICP-490 · NCT05719701 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT05719701
- ICP-490 · NCT06845241 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06845241
- ICP-490 · IKZF1 (Ikaros); IKZF3 (Aiolos) | issuer (innocarepharma.com) | | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf
- P11
- ICP-538 · NCT07535099 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07535099
- ICP-538 · VAV1 | issuer (innocarepharma.com) | | https://www.innocarepharma.com/uploads/2026-03-26/2025-Annual-Report-CN-A.pdf
- P12
- HSK29116 · NCT04861779 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT04861779
- HSK29116 · Bruton tyrosine kinase (BTK) | issuer (disc.static.szse.cn) | | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF
- P13
- UBX-303061 · NCT06590961 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06590961
- P14
- HSK40118 · NCT06050980 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06050980
- HSK40118 · Mutant epidermal growth factor receptor (EGFR) | issuer (disc.static.szse.cn) | | https://disc.static.szse.cn/disc/disk03/finalpage/2026-08-27/8ef41362-8592-467c-8fba-38d4f313eb45.PDF
- P15
- BG-75098 · NCT07226349 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07226349
- BG-75098 · CDK2 | trial investigators or issuer (beonemedicines.com) | | https://beonemedicines.com/wp-content/uploads/2026/11/BeOne-pipeline-4Nov26-Final-.pdf
- P16
- CG001419 · NCT06636500 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06636500
- CG001419 · NCT07394374 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07394374
- CG001419 · TRK | issuer (ir.gyretx.com) | | https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-third-quarter-2026-and-year-date
- P17
- CG009301 · NCT07347171 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07347171
- CG009301 · GSPT1 | issuer (ir.gyretx.com) | | https://ir.gyretx.com/news-releases/news-release-details/gyre-therapeutics-reports-third-quarter-2026-and-year-date
- P18
- PIN-5018 · CK1α | issuer (prnewswire.com) | | https://www.prnewswire.com/news-releases/pin-therapeutics-initiates-first-patient-dosing-of-ck1-degrader-pin-5018-in-phase-1-trial-302624301.html
- P19
- ORM-1153 · NCT07809906 | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT07809906
- ORM-1153 · CD123 / GSPT1 | issuer (orumrx.com) | | https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in
- P20
- May 1, 2026; Veppanu approved after at least one line of endocrine therapy for specified ER-positive HER2-negative ESR1-mutated advanced/metastatic breast cancer | regulator (fda.gov) | | https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
- P21
- August 13, 2026; iberdomide accelerated approval with daratumumab/hyaluronidase and dexamethasone after at least one prior therapy line including a PI and IMiD | regulator (fda.gov) | | https://www.fda.gov/drugs/cancer-approvals/oncology-cancerhematologic-malignancies-approval-notifications?param=8dda41bd
- P22
- Phase 1 CLL/SLL: 57/67 responses (85.1%), includes partial response with lymphocytosis | primary congress abstract (library.ehaweb.org) | | https://library.ehaweb.org/eha/2026/eha-2026/4206706/stephan.stilgenbauer.bgb-16673.a.bruton.tyrosine.kinase.28btk29.degrader.in.html
- P23
- Pivotal Phase 2 component met its primary overall response endpoint in relapsed/refractory CLL | issuer filing (hkexir.beonemedicines.com) | | https://hkexir.beonemedicines.com/media/hk-news/20261105/assets/12402675-0.pdf?disposition=inline
- P24
- Setidegrasib Phase 1, later-line NSCLC: 37.5% objective response among 32 second/third-line participants; PDAC: 24% among 21 second/third-line participants | primary research abstract (pubmed.ncbi.nlm.nih.gov) | | https://pubmed.ncbi.nlm.nih.gov/41879829/?fc=None&ff=20260411131702&v=2.19.0.post6+133c1fe
- 37.5% observed objective response among 32 in second/third-line lung cancer cohort | issuer presentation (astellas.com) | | https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/astellas_csp2026_presentation_20260526_en.pdf
- P25
- Phase 2: 180 enrolled; primary hair count measured after 12 weeks; vehicle-controlled design | primary research abstract (pubmed.ncbi.nlm.nih.gov) | | https://pubmed.ncbi.nlm.nih.gov/41328006/
- Phase 2: 180 actually enrolled; non-vellus target-area hair-count change at 12 weeks | trial registry (clinicaltrials.gov) | | https://clinicaltrials.gov/study/NCT06692465
- P27
- BMS acquired ORM-6151 in 2023 for $100m upfront; Phase 1 discontinued per September 17, 2026 filing | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm
- ORM-6151 Phase 1 discontinuation disclosed on September 17, 2026 | issuer filing index (orumrx.com) | | https://www.orumrx.com/filings
- P28
- 2026 Prazer–Janssen platform research and licensing; deal-specific targets and payment not disclosed | issuer release (prazertx.com) | | https://prazertx.com/pages/board/view.php?board_sid=16&category_code1=&data_sid=278&menu_code=477&page_num=&skey=&sval=
- P29
- 2023 Cullgen–Astellas discovery/option collaboration; US$35m received upfront in licensor accounts | licensor financial statements filed with SEC (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1124105/000114036126028564/ef20077460_ex99-1.htm
- P30
- PROTAC principle: link ligand-binding target to an E3 recruiting moiety, enabling targeted degradation | primary research (pnas.org) | | https://www.pnas.org/doi/10.1073/pnas.141230798
- P31
- HRS-5041 Phase 1 showed PSA responses among subsets of dose cohorts | primary congress abstract (ascopubs.org) | | https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.3112
- P32
- HP518 first-in-human Phase 1 reports activity and pharmacokinetics in mCRPC | primary research abstract (pubmed.ncbi.nlm.nih.gov) | | https://pubmed.ncbi.nlm.nih.gov/40289067/
- P33
- QLH12016 Phase 1 data presented at ESMO; patient responses are preliminary | primary congress abstract (annalsofoncology.org) | | https://www.annalsofoncology.org/article/S0923-7534%2825%2903985-7/abstract
- P34
- 2026 September report confirms GT20029 acne Phase 2 sponsor topline had met its primary endpoint | issuer filing (static.cninfo.com.cn) | | https://static.cninfo.com.cn/finalpage/2026-09-29/1225589146.PDF